Morgan Stanley 22nd Annual
Global Healthcare Conference on September
4 in New York
2024 Wells Fargo Healthcare Conference on
September 5 in Boston
SAN
DIEGO, Aug. 28, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming
investor conferences in September.
- Chief Executive Officer Kevin
Gorman, Chief Business Development and Strategy Officer
Kyle Gano, and Chief Financial
Officer Matt Abernethy will present
at the Morgan Stanley 22nd Annual Global Healthcare
Conference in New York at
3:20 p.m. Eastern Time on Wednesday,
September 4, 2024.
- Kyle Gano and Matt Abernethy will present at the 2024 Wells
Fargo Healthcare Conference in Boston at 8:45 a.m.
Eastern Time on Thursday, September 5, 2024.
The live presentations will be webcast and may be accessed on
Neurocrine Biosciences' website under Investors at
www.neurocrine.com. A replay of the webcasts will be available on
the website approximately one hour after the conclusion of the
event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and
uterine fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn, X
(Formerly Twitter) and Facebook. (*in collaboration with
AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-september-302233393.html
SOURCE Neurocrine Biosciences, Inc.
